<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25287" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Motor Neuron Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Arora</surname>
            <given-names>Rahul D.</given-names>
          </name>
          <aff>Delhi State Health Mission</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khan</surname>
            <given-names>Yusuf S.</given-names>
          </name>
          <aff>Department of Anatomy, College of Medicine, University of Hail, Saudi Arabia.</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rahul Arora declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yusuf Khan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25287.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Motor neuron disease (MND) refers to a group of chronic sporadic and hereditary neurological disorders characterized by progressive degeneration of motor neurons. These might affect the upper motor neurons, lower motor neurons, or both. The prognosis of the motor neuron disease depends upon the age at onset and the area of the central nervous system affected. Amyotrophic lateral sclerosis (ALS) has been documented to be fatal within three years of onset. This activity focuses on amyotrophic lateral sclerosis as the prototype of MND, which affects both the upper and the lower motor neurons and discusses the role of the interprofessional team in the differential diagnosis, evaluation, treatment, and prognostication. It also discusses various other phenotypes of MND with an emphasis on their distinguishing features in requisite detail.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology and pathogenesis of motor neuron disease.</p></list-item><list-item><p>Outline the clinical features and evaluation of a patient with motor neuron disease.</p></list-item><list-item><p>Enumerate strategies in the management of motor neuron disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25287&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25287">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25287.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Motor neuron disease (MND) is said to be a progressive neurological disorder that presents with both lower motor neurons (anterior horn cells that project from the brainstem and the spinal cord to the muscle) and upper motor neuron signs (neurons that project to the brainstem and spinal cord from higher cortical centers).<xref ref-type="bibr" rid="article-25287.r1">[1]</xref></p>
        <p>While the anterior horn cell and the corticospinal tract have been shown to be the primary site of involvement, the involvement of other parts of the nervous system (cortical, autonomic, cerebellar, and extrapyramidal system) has also been documented.<xref ref-type="bibr" rid="article-25287.r1">[1]</xref> The four main phenotypes of motor neuron disease, based upon the site of origin and the severity of neurological involvement, are as follows: Amyotrophic lateral sclerosis, progressive bulbar palsy, progressive muscular atrophy, and primary lateral sclerosis.<xref ref-type="bibr" rid="article-25287.r2">[2]</xref></p>
        <p>Other systems used for the classification of this disease have used the site of onset (spinal or bulbar onset), degree of adherence to the El-Escorial (and Airlie house) criteria, and pattern of heritability (sporadic versus familial) as criteria for characterizing this neurodegenerative illness with a complex genetic basis.<xref ref-type="bibr" rid="article-25287.r3">[3]</xref>&#x000a0;MND has been shown to be a disease of middle age with a mean age of 58&#x000a0;to 63 years at the time of onset for sporadic&#x000a0;Amyotrophic lateral sclerosis (ALS), and 40-60 years of age for familial ALS.<xref ref-type="bibr" rid="article-25287.r4">[4]</xref>&#x000a0;</p>
        <p>There has been a growing ethical debate along with pleas to formulate policies pertaining to the provision of Euthanasia and physician-assisted suicide by the families of patients and their advocates, which has brought the discussion surrounding this disease into the public domain.<xref ref-type="bibr" rid="article-25287.r5">[5]</xref></p>
      </sec>
      <sec id="article-25287.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Existing research points towards an underlying genetic basis. Four genes&#x000a0;are associated with up to 70 percent cases of Familial ALS, namely the C9ORF72, TARDBP, SOD1, and FUS. Over 25 genes and loci have been identified in relation to the predisposition of the disease, amongst which the C9ORF72 (Chromosome 9 open reading frame), has been associated with 40 percent cases of familial and 10 percent cases of sporadic MND. This mutation, which leads to a hexanucleotide repeat expansion, has also been found in cases presenting which Fronto-temporal dementia which has lead to a hypothesis that these neurological disorders exist as part of a dynamic spectrum of neurological syndromes.<xref ref-type="bibr" rid="article-25287.r6">[6]</xref>&#x000a0;This observation also provides evidence for the involvement of extra motor structures in MND spectrum disorders.</p>
        <p>While this particular locus has less than 30 repeats in healthy individuals, patients with C9 related ALS, have a c9orf72 expansion mutation that has hundreds to thousands of repeats.<xref ref-type="bibr" rid="article-25287.r7">[7]</xref>&#x000a0;The presence of this expansion leads to ALS in two different ways. For example, TDP-43 accumulation and repeat-associated non-ATG translation of nuclear RNA foci leading to the formation of repeat derived RNA and dipeptide repeat proteins, which have been postulated to cause neurotoxicity.<xref ref-type="bibr" rid="article-25287.r8">[8]</xref></p>
        <p>TARDBP gene encodes the TAR DNA-binding protein 43, SOD-1 gene encodes for superoxide dismutase. In contrast, the FUS gene codes for the similarly named (Fused in sarcoma) RNA binding protein.<xref ref-type="bibr" rid="article-25287.r8">[8]</xref></p>
        <p>A study of population-based registries of ALS has led a degree of credibility to the hypothesis that ALS follows a complex genetic inheritance, where a variety of environmental factors interact with genetic mutations (present in &#x0201c;at-risk&#x0201d; variants), through a multistep process that decides the pattern of the disease manifestation. The occurrence of rare variants makes extensive genome-wide studies less suited for the study of this disease.<xref ref-type="bibr" rid="article-25287.r9">[9]</xref></p>
        <p>Dysregulation of micro RNA and variations in ion channels that predispose to cellular excitotoxicity has also been postulated as the etiology underlying motor neuron disease.<xref ref-type="bibr" rid="article-25287.r10">[10]</xref></p>
        <p>Familial forms of ALS are also characterized by penetrance of less than 50 percent and genetic pleiotropy (where a single gene can lead to the manifestation of multiple phenotypical traits). In contrast, sporadic forms have been associated with oligogenic (determination of a phenotypic trait by more than one gene) and polygenic inheritance.<xref ref-type="bibr" rid="article-25287.r11">[11]</xref></p>
        <p>Among environmental and lifestyle factors that have been associated with the development of ALS, cyanotoxins, and related compounds deserve mention. The association between the ALS and pre-morbid physical prowess is also an area where some research has been done. An increased incidence in athletes, who have been exposed to repetitive head trauma was proposed, and discarded subsequently, due to the absence of evidence.<xref ref-type="bibr" rid="article-25287.r12">[12]</xref>&#x000a0;Amongst other environmental factors, cigarette smoking, and past history of military service have been consistently shown to be associated with an increased propensity for developing ALS.<xref ref-type="bibr" rid="article-25287.r4">[4]</xref></p>
      </sec>
      <sec id="article-25287.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of motor neuron disease has been shown to approach 2&#x000a0;to 3 per 100,000 population, while a lower frequency (less than 1 per 100,000) of ALS has been demonstrated in the South and East Asian community.<xref ref-type="bibr" rid="article-25287.r13">[13]</xref>&#x000a0;Ancestral origin has been shown to have a significant impact on the disease risk in ALS, with higher survival in racially heterogeneous or admixed populations (as compared to the&#x000a0;White or&#x000a0;Black race community).<xref ref-type="bibr" rid="article-25287.r14">[14]</xref>&#x000a0;A shorter survival has also been reported in European ALS patients (2 years) as compared to the Asian population (4 years).<xref ref-type="bibr" rid="article-25287.r14">[14]</xref>&#x000a0;</p>
        <p>Approximately 10&#x000a0;to 15 percent of individuals with ALS have familial disease.<xref ref-type="bibr" rid="article-25287.r15">[15]</xref>&#x000a0;The estimated lifetime risk of sporadic ALS is one in 400.<xref ref-type="bibr" rid="article-25287.r4">[4]</xref>&#x000a0;While bulbar onset ALS has been shown to be more common in females, spinal onset illness has been shown to be common in males.<xref ref-type="bibr" rid="article-25287.r16">[16]</xref>&#x000a0;Progressive muscular atrophy (PMA) represents 2.5 to 11 percent of cases with MND. With an incidence of 0.02 per 100,000 population, it is a much rarer form of the disease. It is predominantly seen in males, with a male to female ratio ranging from 3&#x000a0;to 7.5&#x000a0;to 1. The median age of onset is of 68 years, which is older than that of ALS patients.<xref ref-type="bibr" rid="article-25287.r17">[17]</xref></p>
      </sec>
      <sec id="article-25287.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Motor neuron injury arising as a result of derangement of multiple interlinked intracellular processes that have been attributed to genetic mutations leading to impaired protein homeostasis (SIGMAR 1M, CHMP2B,c9orf72), aberrant RNA metabolism (SETS, FUS, ANG), mitochondrial dysfunction (SOD1, CHCHD10, TARDBP), dysregulated vesicle transport (SOD1, ALS2, FIG4), impaired DNA repair (NEK1, C21ORF2, SPG11), oxidative stress (SOD 1, ALS2, TARDBP2 mutation), which have all been implicated in the development of neurotoxicity.<xref ref-type="bibr" rid="article-25287.r18">[18]</xref>&#x000a0;</p>
        <p>Out of the processes mentioned above, the two which have been postulated as being central to the etiopathogenesis of the neuronal injury include defects in protein homeostasis and RNA metabolism.<xref ref-type="bibr" rid="article-25287.r19">[19]</xref>&#x000a0;Neuronal hyperexcitability and axonal dysfunction have also been implicated in the etiopathogenesis.<xref ref-type="bibr" rid="article-25287.r20">[20]</xref></p>
        <p>These processes lead to the failure of the motor neuron axon in maintaining its projections leading to retraction of the axon and ultimately resulting in denervation of the target. This leads to denervation of the neuron when the lower motor neuron and loss of supraspinal control of the upper motor neuron, hypertonia, and spastic weakness when the upper motor neuron is involved.<xref ref-type="bibr" rid="article-25287.r21">[21]</xref></p>
      </sec>
      <sec id="article-25287.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The neuropathological hallmark of this disease is the presence of TDP-43 (transactive response DNA binding protein 43) containing ubiquitinylated proteinaceous inclusions in motor neurons.<xref ref-type="bibr" rid="article-25287.r22">[22]</xref>&#x000a0;Nuclear depletion of TDP-43 along with cytoplasmic deposition of atypical cytoskeletal aggregates has been observed in residual motor neurons. Neurofilaments hyaline aggregate inclusions, deposition of misfolded SOD 1 proteins, p62, or sequestosome 1 coded by SQSTM1 have also been identified as the molecular constituents of ubiquitinated aggregates observed in afferent motor neurons.<xref ref-type="bibr" rid="article-25287.r23">[23]</xref>&#x000a0;It has also been hypothesized that the high molecular weight complexes, which precede the development of these aggregates are responsible for the neurotoxicity.<xref ref-type="bibr" rid="article-25287.r24">[24]</xref></p>
        <p>Skeletal muscle and cortical motor atrophy, corticospinal, and corticobulbar tract hyalinization and sclerosis, hypoglossal nerve, and ventral root thinning have been observed on gross examination in pathology specimens.<xref ref-type="bibr" rid="article-25287.r25">[25]</xref>&#x000a0;Microscopically, diseased skeletal muscle fibers demonstrate changes of denervation and reinnervation with the grouping of atrophic and angular fibers.<xref ref-type="bibr" rid="article-25287.r26">[26]</xref>&#x000a0;</p>
        <p>The high expression of Ephrin type a receptor 4 and matrix metalloproteinase 9 along with lower expression osteopontin and Insulin-like growth factor 2 along with the large size of the cell and the need to maintain long axonal projections could make the motor neuron more vulnerable to the effect of these derangements.<xref ref-type="bibr" rid="article-25287.r27">[27]</xref>&#x000a0;It has been seen that motor neurons that comprise the fast fatigable motor units are damaged earlier in the disease process. The importance of this, and relation to other etiological environmental factors, is yet to be elucidated.<xref ref-type="bibr" rid="article-25287.r27">[27]</xref></p>
      </sec>
      <sec id="article-25287.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The diagnosis of MND hinges upon critical clinical observation.<xref ref-type="bibr" rid="article-25287.r28">[28]</xref>&#x000a0;The characterization of weakness should address the following questions - asymmetrical versus symmetrical, proximal versus distal, upper versus lower limb predominance, presence, or absence of bulbar symptoms.<xref ref-type="bibr" rid="article-25287.r29">[29]</xref></p>
        <p>
<italic toggle="yes">
<bold>Amyotrophic lateral sclerosis (ALS):</bold>
</italic>
</p>
        <p>While a majority of ALS patients present with limb onset disease (60-80 percent), about one third to a fifth present with bulbar involvement in the form of dysarthria and dysphagia (along with emotional lability). A small minority of patients present with signs of respiratory muscle weakness. Patients may present with predominantly upper motor neuron (UMN) symptoms (hyperreflexia and spastic weakness) with the lower motor neuron (LMN) signs becoming commoner with the progression of the disease.<xref ref-type="bibr" rid="article-25287.r16">[16]</xref>&#x000a0;Presentation with lower motor neuron signs of flaccid weakness, fasciculations, and muscle wasting may also be seen.</p>
        <p>The initial symptom usually involves the distal muscles asymmetrically manifestation, such as difficulty in turning doorknobs, writing, turning keys in locks, picking up objects from overhead shelves along with impairment of gait, imbalance, and frequent falls which might manifest as functional disability and impairment of activities of daily living.<xref ref-type="bibr" rid="article-25287.r30">[30]</xref>&#x000a0;Progressive dysphagia may lead to a reduction in oral intake and ensuing weight loss.<xref ref-type="bibr" rid="article-25287.r31">[31]</xref>&#x000a0;Amyotrophic lateral sclerosis has also been related to a hypercatabolic state, the etiopathogenesis of which has not been elucidated.<xref ref-type="bibr" rid="article-25287.r32">[32]</xref>&#x000a0;The ability to communicate effectively might be hindered by the development of dysarthria.<xref ref-type="bibr" rid="article-25287.r33">[33]</xref>&#x000a0;</p>
        <p>Respiratory insufficiency may present with breathlessness along with symptoms of carbon dioxide retention (headache) and hypoxia (confusion). Complications arising as a result of respiratory impairment (Respiratory failure and pneumonia) are the leading cause of death.<xref ref-type="bibr" rid="article-25287.r34">[34]</xref>&#x000a0;Impairment of executive function manifesting as inattention, working memory, organization, and planning capabilities are seen in a third of patients.<xref ref-type="bibr" rid="article-25287.r35">[35]</xref>&#x000a0;A tenth of newly diagnosed patients may present with symptoms of Frontotemporal dementia.<xref ref-type="bibr" rid="article-25287.r36">[36]</xref>&#x000a0;</p>
        <p>Behavioral traits such as apathy, changes in personality and mood, disinhibition, and obsessive behavior are also being recognized increasingly in this subset of patients.<xref ref-type="bibr" rid="article-25287.r37">[37]</xref>&#x000a0;The symptoms present in nearly forty percent of patients at presentation can be clustered into five different groups, which have been known to map to known neuroanatomical networks.<xref ref-type="bibr" rid="article-25287.r38">[38]</xref></p>
        <p>A degree of severe autonomic impairment with the potential to impact the quality of life is usually not seen in patients with ALS.&#x000a0;Upper motor neuron involvement has been associated with more severe autonomic deficits.<xref ref-type="bibr" rid="article-25287.r39">[39]</xref></p>
        <p>
<italic toggle="yes">
<bold>Progressive muscular atrophy (PMA):</bold>
</italic>
</p>
        <p>Also known as the LMN phenotype, and represents 5 percent of the MND cases. It presents with progressively worsening LMN signs. The upper motor neuron signs are known to develop in 20-30 percent of the cases, usually within 5&#x000a0;to 10 years of the onset of the disease. Patients present with typical LMN symptoms of progressive flaccid paralysis, muscle atrophy, hyporeflexia/areflexia, and fasciculations.</p>
        <p>Asymmetric weakness and atrophy in the distal limbs are seen at presentation. It is associated with a relatively better prognosis and characterized by a slower rate of progression. The asymmetrical proximal muscle weakness pattern is seen in a fifth of the patients. Bulbar involvement portends a poorer prognosis.<xref ref-type="bibr" rid="article-25287.r40">[40]</xref>&#x000a0;Axial or respiratory muscle involvement is uncommon at the onset but may predict a poor prognosis when present.<xref ref-type="bibr" rid="article-25287.r41">[41]</xref>&#x000a0;Cognitive impairment in MND is linked with UMN involvement and is rarely seen in PMA.<xref ref-type="bibr" rid="article-25287.r42">[42]</xref></p>
        <p>Flail arm and flail leg variants are other lower motor neuron variants of MND.<xref ref-type="bibr" rid="article-25287.r40">[40]</xref>&#x000a0;While, the flail arm variant is characterized by progressive, predominant upper limb involvement, proximal to distal progression, the flail leg variant is known to present with progressive, asymmetric weakness of the lower limbs.</p>
        <p>Family history of a similar neurological illness, personal account of smoking, exposure to toxins (cyanotoxins) assumes importance, occupational history of military service and past history of repetitive head trauma (as in pugilists) also needs to be ruled out in patients suspected to have a working diagnosis of ALS.<xref ref-type="bibr" rid="article-25287.r43">[43]</xref>&#x000a0;Past medical history of HIV also needs to be ruled out as it has been shown to be associated with an ALS like syndrome, which is shown to improve with antiretroviral therapy.<xref ref-type="bibr" rid="article-25287.r44">[44]</xref></p>
        <p>
<italic toggle="yes">
<bold>Physical examination:</bold>
</italic>
</p>
        <p>An examination may reveal a constellation of upper motor neuron and lower motor neuron signs. Upper motor neuron signs range from hyperreflexia, spastic weakness, and exaggerated jaw jerk to clonus. In contrast, lower motor neuron involvement is characterized by areflexia or hyporeflexia, flaccid weakness, wasting, and fasciculations.<xref ref-type="bibr" rid="article-25287.r45">[45]</xref></p>
        <p>Bulbar involvement is characterized by dysarthria and dyspnoea, which might also be accompanied by emotional liability.<xref ref-type="bibr" rid="article-25287.r16">[16]</xref>&#x000a0;A neuropsychiatric assessment may present with signs of executive dysfunction and behavioral abnormalities.<xref ref-type="bibr" rid="article-25287.r46">[46]</xref>&#x000a0;Extraocular muscle and sphincter involvement are rare in the typical variant of the disease.<xref ref-type="bibr" rid="article-25287.r47">[47]</xref></p>
        <p>Identification of specific patterns of limb weakness may provide an aid to the physical diagnosis of ALS. In this split hand pattern, there is a preferential involvement of the first dorsal interossei and the thenar muscles with sparing of hypothenar muscles. In contrast, the split leg pattern is characterized by preferential ankle plantar flexion involvement with the sparing of the dorsiflexors.<xref ref-type="bibr" rid="article-25287.r48">[48]</xref></p>
        <p>
<italic toggle="yes">
<bold>Physical signs in ALS:</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fasciculations, if generalized (can be easily missed over the shoulders)<xref ref-type="bibr" rid="article-25287.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Bilateral wasting of the tongues &#x02013; lateral borders, particularly when there are also fasciculations with a brisk jaw jerk and orbicularis oculi reflexes</p>
          </list-item>
          <list-item>
            <p>The &#x0201c;split hand&#x0201d;- preferential wasting of the lateral border of the hand, first dorsal interosseous and abductor policies Brevis, though to reflect the cortical organization</p>
          </list-item>
          <list-item>
            <p>Head drop due to weakness of neck extensors, may consider an alternative diagnosis of myasthenia gravis. Care should be exercised to not attribute this sign to degenerative cervical sign<xref ref-type="bibr" rid="article-25287.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Emotionality &#x02013; exaggerated response to emotional stimuli, usually crying, bulbar weakness may be present. An abnormal response to the glabellar tap may be seen<xref ref-type="bibr" rid="article-25287.r50">[50]</xref></p>
          </list-item>
          <list-item>
            <p>Cognitive or behavioral disorders &#x02013; Frontotemporal dementia overlap features<xref ref-type="bibr" rid="article-25287.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25287.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Essential investigations advised in the evaluation of a patient are complete blood count, erythrocyte sedimentation rate, C&#x02013;reactive protein, full biochemical count (including thyroid function tests and calcium), creatine kinase (more than 1000iu/l are very unusual in MND patients), immunoglobulins and serum electrophoresis. The electromyography, nerve conduction studies, MRI of the brain, and spine are also advised.<xref ref-type="bibr" rid="article-25287.r51">[51]</xref></p>
        <p>Nerve conduction studies can be used in assessing the type of pattern of involvement, the existence of&#x000a0;demyelination or focal motor conduction block, and the existence of subclinical sensory abnormalities.<xref ref-type="bibr" rid="article-25287.r40">[40]</xref>&#x000a0;Optional investigations include vitamin B12, folate, anti-acetylcholine receptor antibodies, HIV, Lyme&#x02019;s serology, lumbar puncture, and muscle biopsy, which might be useful in ruling out other differential diagnoses.</p>
        <p>The diagnosis of ALS is based upon recognition of a specific pattern of weakness, ruling out other etiologies that may present with similar symptoms and ascertainment of disease progression. Various diagnostic criteria include the El Escorial, Airlie house, Awaji, and ALS diagnostic index.<xref ref-type="bibr" rid="article-25287.r2">[2]</xref>&#x000a0;These criteria require the demonstration of the three features. Those are the demonstration of clinical, electrophysiological or neuropathological lower motor neuron degeneration, evidence of clinical involvement of upper motor neurons, and progression of the disease from one region to the other by neurological or electrophysiological testing.&#x000a0;For the purpose of diagnosis, specific patterns of involvement confined to one particular area have been identified, namely the bulbar, cervical, thoracic, and lumbar region.<xref ref-type="bibr" rid="article-25287.r2">[2]</xref></p>
        <p>While the categories of diagnostic certainty, ranged from suspected ALS to definitive ALS in the El Escorial criteria, the Airlie house criteria demarcate these clinical features and laboratory supported findings into categories ranging from definitive ALS to possible ALS.<xref ref-type="bibr" rid="article-25287.r2">[2]</xref>&#x000a0;The Awaji criteria allow the inclusion of electrophysiological parameters into the diagnostic parameters, while the ALS diagnostic index includes transcranial magnetic stimulation defined standards that can be used to determine the functional integrity of the upper motor neuron. Threshold tracking TMS (transcranial magnetic stimulation) has demonstrated evidence of cortical hyperexcitability in MND and may provide objective evidence of clinically inapparent UMN dysfunction.<xref ref-type="bibr" rid="article-25287.r3">[3]</xref></p>
        <p>
<bold>Biomarkers:</bold>
</p>
        <p>Various biomarkers such as neurofilament light peptide and phosphorylated neurofilament heavy neuropeptides in cerebrospinal fluid (CSF) have been used to differentiate ALS from its mimics, namely, cervical myelopathy, multifocal motor neuropathy, and inclusion body myositis.<xref ref-type="bibr" rid="article-25287.r52">[52]</xref>&#x000a0;Levels of these CSF biomarkers have been found to be specific and sensitive to diagnose patients with ALS and have also been shown to correlate with disease progression.</p>
        <p>Though abnormalities on FDG PET (F-fluorodeoxyglucose positron emission tomography) imaging and spectral electroencephalography have identified selective network disruptions in structural and functional connectomes (corticospinal, orbitofrontal, frontostriatal and orbitotemporal circuits), they have not been found to be clinically useful in establishing a diagnosis of motor neuron disease with certainty.<xref ref-type="bibr" rid="article-25287.r53">[53]</xref></p>
      </sec>
      <sec id="article-25287.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Disease-modifying Therapies</bold>
</p>
        <p>Riluzole, an NMDA (N-methyl-D-aspartate) receptor antagonist, reduces glutaminergic transmission by acting on the presynaptic voltage-gated sodium channels. Relative glutamate excess has been shown to lead to upper and lower motor neuron excitotoxicity contributing to neuronal cell death.<xref ref-type="bibr" rid="article-25287.r54">[54]</xref> It has been shown to be associated with a statistically significant improvement in tracheostomy free survival.<xref ref-type="bibr" rid="article-25287.r55">[55]</xref> Though sustained use for 18 months was not associated with improved muscle strength, it has been shown to improve survival by three months (equitable to a 9 percent increase in one-year survival).<xref ref-type="bibr" rid="article-25287.r56">[56]</xref> It was found to be very useful in those with moderate functional impairment in those with advanced disease when used on a compassionate basis.<xref ref-type="bibr" rid="article-25287.r57">[57]</xref></p>
        <p>The standard dose of Riluzole in the management of ALS is 50 mg two times daily.<xref ref-type="bibr" rid="article-25287.r58">[58]</xref> The most common adverse effects include nausea, asthenia, and derangement in liver enzymes.<xref ref-type="bibr" rid="article-25287.r57">[57]</xref> Pancreatitis and fulminant hepatic failure have also been reported as rare adverse effects.<xref ref-type="bibr" rid="article-25287.r59">[59]</xref> Regular blood testing every month for the first three months, followed by three monthly for nine months and yearly, is recommended.<xref ref-type="bibr" rid="article-25287.r60">[60]</xref> An increase&#x000a0;of over three times the upper limit of normal in hepatic enzymes can be managed by dose reduction, followed by withdrawal followed by the re-introduction of the drug<xref ref-type="bibr" rid="article-25287.r60">[60]</xref>. Riluzole is contraindicated in hepatic and renal impairments and in those who are breastfeeding and lactating. Further trials have been advised to test the efficacy of different dosing regimens.<xref ref-type="bibr" rid="article-25287.r61">[61]</xref></p>
        <p>Edaravone has also been shown to impede disease progression in those patients with early-onset disease and rapid disease progression.<xref ref-type="bibr" rid="article-25287.r62">[62]</xref> Its role in the management of all patients with ALS remains to be addressed.<xref ref-type="bibr" rid="article-25287.r63">[63]</xref> The drug acts as an antioxidant, which has been shown to prevent the nitration of tyrosine residues in experimental animal models.<xref ref-type="bibr" rid="article-25287.r64">[64]</xref></p>
        <p>
<bold>Symptom Directed Treatment</bold>
</p>
        <p>
<italic toggle="yes">
<bold>Spasticity:</bold>
</italic>
</p>
        <p>Spasticity may be present in most of the patients with primary lateral sclerosis, though it may only be present with a lesser frequency in patients with amyotrophic lateral sclerosis.<xref ref-type="bibr" rid="article-25287.r65">[65]</xref> Tools to measure spasticity have included the modified Ashworth scale, numerical rating scale spasticity responses, and the Rasch based scale for patient-reported spasticity, among others.<xref ref-type="bibr" rid="article-25287.r66">[66]</xref> Gabapentin, baclofen, tizanidine, benzodiazepines, and levetiracetam have been advised for the management of spasticity. The&#x000a0;practice of these drugs is limited by the occurrence of fatigue and weakness.<xref ref-type="bibr" rid="article-25287.r67">[67]</xref> Baclofen may sometime induce hyperpolarisation of some of the afferent terminals and also inhibits monosynaptic and polysynaptic reflexes usually at the spinal level.<xref ref-type="bibr" rid="article-25287.r68">[68]</xref>&#x000a0;Intrathecal baclofen, wherein the drug is infused into the cerebrospinal fluid through a surgically placed infusion pump, has also been used in the management of spasticity in primary progressive aphasia.<xref ref-type="bibr" rid="article-25287.r69">[69]</xref> Stages of the disease.<xref ref-type="bibr" rid="article-25287.r16">[16]</xref>&#x000a0;</p>
        <p>Siallorhoea is caused by the inability to swallow saliva, which may be the result of tongue spasticity, weakness of the facial, mouth and pharyngeal muscles, loss of pharyngeal coordination, and function.<xref ref-type="bibr" rid="article-25287.r70">[70]</xref>&#x000a0; Anticholinergic drugs such as atropine, hyoscine, glycopyrrolate, and amitryptiline have been found to be beneficial in the management of sialorrhea. Salivary gland irradiation and botulinum toxin injections have also been proposed as treatment modalities.<xref ref-type="bibr" rid="article-25287.r16">[16]</xref> Anticholinergic drugs have been associated with urinary retention and constipation. They are contraindicated in patients with heart block and benign prostatic hypertrophy.<xref ref-type="bibr" rid="article-25287.r1">[1]</xref> Optimum advice on diet, swallowing, positioning, posture, hydration, and oral care should be provided. Nebulizers, humidifiers, and mucolytics should be considered.<xref ref-type="bibr" rid="article-25287.r71">[71]</xref></p>
        <p>
<italic toggle="yes">
<bold>Pain:</bold>
</italic>
</p>
        <p>15% to 85% of patients, more commonly nociceptive than neuropathic in nature. Later stages of the&#x000a0;ailment may be characterized by musculoskeletal pain, which arises as a result of the loss of protective sheath comprising of muscles that protect the bones and joints. Muscle contractures and bone stiffness may also be a source of pain. Decubitus ulcers seen in 16 percent of patients may also be associated with pain. Increased intensity of pain in the later stages of the disease has also been associated with assisted suicide.<xref ref-type="bibr" rid="article-25287.r72">[72]</xref> While, NSAIDs, opioids, and cannabinoids have been used for nociceptive pain, gabapentinoids, and tricyclic antidepressants have been used in neuropathic pain. The dearth of randomized data on this topic is a matter of some concern. Intra-articular injections of lidocaine, along with physical therapy and assistive range of motion exercises, have also been helpful.<xref ref-type="bibr" rid="article-25287.r72">[72]</xref></p>
        <p>
<italic toggle="yes">
<bold>Muscle cramps:</bold>
</italic>
</p>
        <p>Cramps are caused by the instability of motor units.<xref ref-type="bibr" rid="article-25287.r1">[1]</xref> Quinine sulfate, mexiletine, and levetiracetam have been used in ameliorating these symptoms. Caution is advised with the use of quinine sulfate as it has been associated with QT prolongation, arrhythmias, and bradycardia.</p>
        <p>
<italic toggle="yes">
<bold>Dysphagia:</bold>
</italic>
</p>
        <p>Strategies to mitigate this particularly distressing symptom include dietary changes. That consists of the change in consistency of the diet, high calories, and high protein diets, fluid thickeners along with exercises to facilitate swallowing. Insertion of a percutaneous gastrostomy tube for enteral nutrition has also been advised in those with a weight loss&#x000a0;in excess of five percent and in whom swallowing can be associated with the occurrence of dangerous complications. In those in whom these procedures are contraindicated or those with respiratory insufficiency, feeding through a central venous catheter should be tried.<xref ref-type="bibr" rid="article-25287.r1">[1]</xref></p>
        <p>
<italic toggle="yes">
<bold>Dysarthria:</bold>
</italic>
</p>
        <p>Up to 30 percent of the patients with ALS develop dysarthria. This might extend to 80 percent of patients during the course of the disease.<xref ref-type="bibr" rid="article-25287.r1">[1]</xref> Speech therapy, use of customized software for augmentative and alternative software have been shown to enhance the quality of life in ALS.<xref ref-type="bibr" rid="article-25287.r73">[73]</xref></p>
        <p>
<bold><italic toggle="yes">Coagulation abnormalities</italic>&#x000a0;<italic toggle="yes">(Deep venous thrombosis):</italic></bold>
</p>
        <p>The annual incidence of coagulation abnormalities has been in the range of 3 and 11 percent. The use of prophylaxis, compression stockings, and standard doses of anticoagulation as per existing guidelines have been advised.<xref ref-type="bibr" rid="article-25287.r74">[74]</xref></p>
        <p>
<italic toggle="yes">
<bold>Neuropsychiatric disturbances:</bold>
</italic>
</p>
        <p>Neuropsychiatric disturbances such as pseudobulbar affect and depression have been reported.<xref ref-type="bibr" rid="article-25287.r75">[75]</xref> The pseudobulbar effect has been postulated to be caused due to the disruption of the corticopontocerebellar pathways. Impaired volitional control and cerebellar demodulation have been considered central to the neuropathogenesis of this symptom.<xref ref-type="bibr" rid="article-25287.r76">[76]</xref> It has also been described as dysmetria caused due to cerebellar dysmodulation. Depression may be an early manifestation of frontal lobe dysfunction and may signify widespread cortical involvement.<xref ref-type="bibr" rid="article-25287.r77">[77]</xref> Tricyclic depressants and selective serotonin reuptake inhibitors (SSRIs) have been used in the management of depression. Pseudobulbar effects have been managed with the use of these antidepressants.<xref ref-type="bibr" rid="article-25287.r78">[78]</xref> Dextromethorphan and quinidine have also been shown to be useful in the management of this symptom.</p>
        <p>Though no specific agents have been found to be useful in the treatment of cognitive symptoms, SSRIs have been found to be helpful in controlling symptoms such as control of loss of inhibition, overeating, and compulsive behaviors. In contrast, antipsychotics have been found helpful in the treatment of restlessness.</p>
        <p>
<italic toggle="yes">
<bold>Respiratory symptoms:</bold>
</italic>
</p>
        <p>The weakness of respiratory muscles may present in the form of the loss of ability to cough and respiratory insufficiency.<xref ref-type="bibr" rid="article-25287.r79">[79]</xref> The monitoring of physiological parameters of respiratory function has been advised as respiratory symptoms have been found to poorly correlate with respiratory muscle function.<xref ref-type="bibr" rid="article-25287.r80">[80]</xref> Supine Forced vital capacity (FVC) may be used as a marker of diaphragmatic weakness.<xref ref-type="bibr" rid="article-25287.r81">[81]</xref> Methods to assist the patient while coughing (cough assist devices such as physiotherapy maneuvers like tussive squeeze, mechanical insufflator &#x02013; exsufflator devices) have been advised.<xref ref-type="bibr" rid="article-25287.r82">[82]</xref> The usage of non-invasive ventilation (NIV) has been associated with improvement in parameters of respiratory function, which is also associated with an improvement in the quality of life, along with a substantial increase in survival.</p>
        <p>The presence of dyspnoea, orthopnoea, and daytime fatigue, vital capacity less than 80 percent of the normal, partial pressure of CO2 more than 45 mm of Hg, nocturnal hypoventilation (when the oxygen saturation is less than 88-90 percent for more than 5 percent of the time is asleep), maximal inspiratory pressure less than 60 percent predicted, sitting fixed vital capacity less than 50 percent, sniff nasal inspiratory pressure less than 40 percent have been listed as various indications for non-invasive ventilation. NIV is poorly tolerated in 30 percent of patients due to anxiety, emotional lability from pseudobulbar damage, hypersalivation, claustrophobia, and soreness of the nasal bridge.<xref ref-type="bibr" rid="article-25287.r83">[83]</xref> The presence of bulbar dysfunction at the onset and cognitive impairment has been shown to correlate with poor compliance.<xref ref-type="bibr" rid="article-25287.r84">[84]</xref></p>
        <p>Persistent respiratory insufficiency, despite the use of NIV and severe bulbar dysfunction, has been reported as indications for tracheostomy.<xref ref-type="bibr" rid="article-25287.r85">[85]</xref></p>
        <p>The use of diaphragmatic muscle pacing, where four electrodes are placed on the motor roots of the phrenic nerve on the abdominal surface of the diaphragm has also been studied.<xref ref-type="bibr" rid="article-25287.r86">[86]</xref> The procedure involves the implantation of intramuscular electrodes on the abdominal surface of the hemidiaphragm at motor points. Intramuscular diaphragmatic pacing aims to make the diaphragm contract, strengthen the force of contraction, and lead to a decrease in the patient&#x02019;s dependence upon mechanical ventilation. After implantation, the patient undergoes a conditioning program that involves gradual weaning from the ventilator. Current evidence suggests long term safety concerns related to the occurrence of adverse events such as capnothorax or pneumothorax, acute respiratory failure requiring mechanical ventilation, venous thromboembolism, and gastrostomy tube placement. Suture granuloma, infection at the stimulation cable entry point, and superficial wound infection has also been reported.<xref ref-type="bibr" rid="article-25287.r86">[86]</xref></p>
        <p>
<italic toggle="yes">
<bold>Fatigue:</bold>
</italic>
</p>
        <p>Fatigue has been reported as a frequent and debilitating symptom characterized by reversible weakness. It is characterized by a feeling of tiredness, which is not relieved by rest. Both pharmacological measures (Modafinil) and non-pharmacological measures (resistance exercise, respiratory exercise, and repetitive transcranial magnetic stimulation) have been used in the management of fatigue. The quality of evidence for the effectiveness of these interventions has been reported to be very low, and more research is needed on this topic.<xref ref-type="bibr" rid="article-25287.r87">[87]</xref></p>
        <p>
<bold>Palliative Medicine Interventions</bold>
</p>
        <p>Palliative medicine interventions include adequate symptom control, prognostication about goals of care, discussions surrounding degree of aggressiveness of treatment, advanced care planning, provision of quality home-based care, possible liaison with organizations providing community palliative services,&#x000a0; anticipatory prescribing, provision of support to family members (addressing caregiver burden), and bereavement support.</p>
        <p>Formal care at the end of life should incorporate measures to improve the quality of life (such as a system to enable effective communication) and focus upon the management of commonly encountered symptoms. The use of opioids and benzodiazepines for breathlessness, glycopyrrolate for increased secretions, antipsychotics for delirium, and other non-pharmacological treatment options may be indicated in patients approaching their end of life.<xref ref-type="bibr" rid="article-25287.r88">[88]</xref></p>
        <p>Reduction in ICU utilization at end of life, the number of deaths inside the hospital setting (transition in the place of care), and costs of treatment are essential indicators of the efficacy of provision of high-quality care.<xref ref-type="bibr" rid="article-25287.r89">[89]</xref> For patients being treated in the intensive care setting, discussions centering upon withdrawal of life-sustaining measures and DNCPR (Do not perform cardiopulmonary resuscitation) decisions may be indicated.<xref ref-type="bibr" rid="article-25287.r90">[90]</xref></p>
        <p>
<bold>Physiotherapy</bold>
</p>
        <p>Exercise programs such as structured exercise programs may improve stiffness, prevent contractures, reduce discomfort, and optimize the quality of life. Provision of the orthosis, if necessary, should be facilitated without delay.<xref ref-type="bibr" rid="article-25287.r91">[91]</xref></p>
        <p>
<bold>Communication</bold>
</p>
        <p>Communication should be assessed by a speech and language therapist. Constant review during interdisciplinary meets is advised. The provision of augmentative and alternative communication strategies that cause the least interference with the patient&#x02019;s quality of life is recommended.<xref ref-type="bibr" rid="article-25287.r92">[92]</xref></p>
        <p>
<bold>Future therapeutic options</bold>
</p>
        <p>The use of antisense oligonucleotides in SOD 1 related and C9orf related ALS are subjects of research in future clinical trials.<xref ref-type="bibr" rid="article-25287.r93">[93]</xref></p>
        <p>
<bold>Use of stem cell therapy</bold>
</p>
        <p>The proposed mechanism of the utility of stem cell therapy includes the differentiation of stem cells into spinal neurons that synapse with existing motor neurons to establish or maintain neurocircuitry and provide neurotrophic support. Differentiation of stem cells into non-neuronal cells can also impact disease progression by providing neurotrophic support, preventing oligodendrocyte dysfunction and toxicity. Peripheral stem cell transplantation can maintain the neuromuscular junction. The immunomodulatory effect of mesenchymal stem cells mobilized from the bone marrow can also attenuate the inflammatory response via the production of anti-inflammatory mediators. The commonly used stem cell therapies include olfactory ensheathing stem cells, endogenous mesenchymal stem cells, autologous mesenchymal stem cells, and neural progenitor cells. The most significant number of trials of stem cell therapy involves the use of mesenchymal stem cells.<xref ref-type="bibr" rid="article-25287.r94">[94]</xref></p>
      </sec>
      <sec id="article-25287.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The most common disease that mimics the&#x000a0;amyotrophic lateral sclerosis is none other than degenerative spondylotic myeloradiculopathy in the cervical and/or lumbosacral spine, which may present with radicular pain. This may be characterized by progressive symptoms that plateau later with the progression of the disease. Although imaging has been advised to differentiate between the two entities, there may be the presence of co-existent degenerative illness in those with ALS.<xref ref-type="bibr" rid="article-25287.r51">[51]</xref></p>
        <p>Presentation with symmetrical findings, prominent extensor plantar responses (cervical myelopathy), presence of sensory deficit, presence of substantial weakness in the absence of wasting (multifocal motor neuropathy and myasthenia gravis) and disproportionate involvement of quadriceps (inclusion body myositis) should prompt further investigation for an alternative diagnosis.</p>
        <p>An acute presentation of lower motor neuron syndrome should prompt consideration of immune, toxic, metabolic, and infective etiology. The major differentials include MND, multifocal motor neuropathy, and monomelic amyotrophy.<xref ref-type="bibr" rid="article-25287.r40">[40]</xref>&#x000a0;The diagnosis of multifocal motor neuropathy should be considered in patients with early involvement of finger and wrist extensors, focal motor conduction block, presence of positive symptoms such as cramps, spasms, and presence of anti-IgM GM -1 antibody.<xref ref-type="bibr" rid="article-25287.r95">[95]</xref></p>
        <p>
<italic toggle="yes">
<bold>Motor neuron disease mimics:</bold>
</italic>
</p>
        <p>
<bold>a. Presenting with progressive, painless weakness</bold>
<xref ref-type="bibr" rid="article-25287.r51">[51]</xref>
</p>
        <p>i) <italic toggle="yes">Genetic disorders</italic> &#x02013; Spinal muscular atrophy, Kennedy&#x02019;s disease, hexosaminidase deficiency, mitochondrial disease, triple-A (Allgrove syndrome), polyglucosan body disease, hereditary spastic paraparesis, and adrenoleukodystrophy.</p>
        <p>ii) <italic toggle="yes">Toxicity or metabolic disorders</italic> &#x02013; Radiation myelopathy, thyrotoxicosis, hyperparathyroidism, lead poisoning, mercury poisoning, and copper deficiency.</p>
        <p>iii) <italic toggle="yes">Infectious diseases</italic> &#x02013; Post-polio syndrome, Lyme disease, and HIV.</p>
        <p>iv)<italic toggle="yes"> Immunological or inflammatory syndromes</italic> &#x02013; Paraproteinemic neuropathy, conduction block neuropathy, Sjogren&#x02019;s syndrome, Inclusion body myositis, Gluten sensitivity, myasthenia gravis, and polymyositis.</p>
        <p>v) <italic toggle="yes">Structural diseases</italic> &#x02013; Spondylotic myelopathy, the base of skull lesions, foramen magnum lesions, intrinsic or extrinsic cord tumors, and lumbosacral radiculopathies.</p>
        <p>vi) <italic toggle="yes">Miscellaneous condition</italic> &#x02013; Cramp fasciculation syndromes, paraneoplastic disease, lymphoproliferative disease, and paraneoplastic neuromuscular disease.</p>
        <p>
<bold>b. Presenting with a generalized or focal single (monomelic) limb onset lower motor neuron syndromes</bold>
<xref ref-type="bibr" rid="article-25287.r51">[51]</xref>
</p>
        <p>i) <italic toggle="yes">Brachial neuritis / Parsonage-Turner syndrome</italic><xref ref-type="bibr" rid="article-25287.r96">[96]</xref></p>
        <p>Sudden onset typically idiopathic inflammatory condition affecting the brachial plexus, characterized by severe pain followed by weakness and wasting in the absence of trauma. Five percent of cases may be painless. History of preceding viral illness or vaccination may be present. In 10 percent of the cases, there may be a bilateral pathology. A history of bilateral phrenic nerve paralysis, producing diaphragmatic palsy leading to orthopnoea, may also be present.</p>
        <p>ii) <italic toggle="yes">Hirayama&#x02019;s disease</italic><xref ref-type="bibr" rid="article-25287.r97">[97]</xref></p>
        <p>Benign juvenile-onset monomelic amyotrophy of the upper limb or focal segmental spinal muscular atrophy may be progressive for 1&#x000a0;to 3 years, and then remain stable, may not show progression or recovery. Sub-clinical involvement of another limb may be apparent on NCS/EMG. May present with cold paresis or oblique amyotrophy of the forearm, commonly seen in Japan and the Indian subcontinent.</p>
        <p>iii) <italic toggle="yes">Kennedy&#x02019;s syndrome</italic><xref ref-type="bibr" rid="article-25287.r98">[98]</xref></p>
        <p>Spinobulbar muscular atrophy, trinucleotide repeat mutation in the first exon of the androgen receptor gene, develop symptoms in the 4th and 5th decade, LMN syndrome, slowly progressive, bulbar weakness, tongue wasting, disproportionate bulbar involvement, lower facial/chin (mentalis) fasciculation characteristic, sensory as well as motor neuropathy may be seen. Gynecomastia, partial feminization, small testes, may cause respiratory insufficiency, associated with average life expectancy.</p>
        <p>iv) <italic toggle="yes">Inclusion body myositis</italic><xref ref-type="bibr" rid="article-25287.r99">[99]</xref></p>
        <p>Slowly evolving painless symmetrical weakness, distal weakness, weakness distal or characteristic involvement of the quadriceps and long finger flexors (medial forearm), dysphagia,&#x000a0; creatine kinase modestly elevated to within 2-10 times the normal range (important diagnostic clue). Usually aged over 50 years, 3&#x000a0;to 1 female to male predilection, EMG may appear neurogenic with fibrillation potentials. Muscle biopsy may show rimmed vacuoles, with inflammatory changes, relentless progression over the years, significant disability, and impairment of quality of life. Rare hereditary forms of inclusion body myositis may be associated with MND and frontotemporal dementia, in which mutations in the gene encoding for valosin containing protein and muscle biopsies stain for the protein TDP-43. This is the characteristic protein that accumulates in the central nervous system in such patients.</p>
        <p>
<bold>c. Upper motor neuron signs</bold>
<xref ref-type="bibr" rid="article-25287.r51">[51]</xref>
</p>
        <p>i) <italic toggle="yes">Hereditary spastic paraparesis</italic><xref ref-type="bibr" rid="article-25287.r29">[29]</xref></p>
        <p>Younger onset, slowly progressive paraplegia, dorsal column involvement, sphincter dysfunction, may include symptoms of ataxia or dementia, especially with a positive family history (autosomal dominant). Forty percent have mutations in the SPAST gene; minimal upper limb involvement does not include severe corticobulbar involvement. &#x000a0;</p>
        <p>ii) <italic toggle="yes">Primary progressive multiple sclerosis</italic><xref ref-type="bibr" rid="article-25287.r29">[29]</xref></p>
        <p>Slowly progressive, positive CSF findings (oligoclonal bands) and demyelination.&#x000a0;</p>
        <p>iii) <italic toggle="yes">Metabolic myelopathies</italic><xref ref-type="bibr" rid="article-25287.r29">[29]</xref></p>
        <p>Vitamin B12 and copper associated myelopathies, slowly progressive myelopathy, typically associated with sensory neuropathy, and adult-onset slowly progressive myelopathy,</p>
        <p>iv) <italic toggle="yes">X linked adrenoleucodystrophy</italic><xref ref-type="bibr" rid="article-25287.r29">[29]</xref></p>
        <p>A peroxisomal disorder involving the ABCD1 transporter, long-chain fatty acid transporter, presents typically in the third to a fourth decade, confined to lower limbs, may present with sensory ataxia and bladder symptoms. Secondary Wallerian degeneration may result in hyperintensities in the associated cerebral corticospinal tracts.</p>
      </sec>
      <sec id="article-25287.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Negative prognostic indicators &#x02013; These include the bulbar onset or respiratory onset disease, presence of executive impairment, frontotemporal dementia, and weight loss, worsening respiratory function indicated by a reduction in serially assessed forced vital capacity, and also sniff nasal inspiratory pressure.</p>
        <p>Symptoms such as speech and swallowing problems, weight loss, reduced respiratory function, older age, lower amyotrophic lateral sclerosis functional rating scale, shorter time from developing first symptoms to time of diagnosis have been identified as factors that might indicate a poor prognosis.<xref ref-type="bibr" rid="article-25287.r100">[100]</xref></p>
        <p>King&#x02019;s criteria that include the number of body regions affected and the presence of respiratory/nutritional failure and Milano-Torino system (records changes in domains of bulbar, fine motor, gross motor, and respiratory function), are used in clinical staging. While the King&#x02019;s system has been shown to be sensitive to changes early in the trajectory of the disease, the MITOS system has been shown to be more sensitive to detect changes in the late stages of the disease).<xref ref-type="bibr" rid="article-25287.r101">[101]</xref></p>
        <p>These staging systems have come under criticism for not including the domains of cognitive and affective function within their purview. However, scales such as the Edinburgh cognitive and behavioral functional (ALS) stream (ECAS),&#x000a0;the detection of affective and cognitive dysfunction is vital as the presence of executive impairment has been associated with a more progressive downward disease trajectory while being shown to be related to specific needs that have the impact on increasing caregiver burden.<xref ref-type="bibr" rid="article-25287.r102">[102]</xref></p>
      </sec>
      <sec id="article-25287.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Most patients with ALS die of respiratory failure within three years of the onset of the disease.<xref ref-type="bibr" rid="article-25287.r34">[34]</xref>&#x000a0;Progressive weakness and wasting of the limb and respiratory muscles have been attributed to be the underlying precipitants of respiratory failure. Severe dysphagia may lead to weight loss, choking, and aspiration.<xref ref-type="bibr" rid="article-25287.r103">[103]</xref>&#x000a0;Prolonged effortless mealtimes and coughing on attempting to swallow are other factors that have the ability to impact the patient's quality of care.<xref ref-type="bibr" rid="article-25287.r104">[104]</xref>&#x000a0;</p>
        <p>Progressive deterioration in the activities of daily living, inability to ambulate, issues related to prolonged immobilization such as superficial skin infections, decubitus ulcers, and deep venous thrombosis are also seen in these patients.<xref ref-type="bibr" rid="article-25287.r105">[105]</xref><xref ref-type="bibr" rid="article-25287.r106">[106]</xref></p>
      </sec>
      <sec id="article-25287.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A multidisciplinary team consisting of neurologists, respiratory physicians, physical medicine, and rehabilitation specialists (respiratory physiotherapists), gastroenterologists, dieticians may have an active role in the management of the patient. Palliative medicine input may be required for the management of pain, difficult to control symptoms (such as resistant breathlessness at the end of life), and psychosocial issues.<xref ref-type="bibr" rid="article-25287.r88">[88]</xref>&#x000a0;The inclusion of social care practitioners and staff who have been trained to manage patients, in the setting of their homes, in the multidisciplinary team has also been advised.<xref ref-type="bibr" rid="article-25287.r107">[107]</xref>&#x000a0;Identification of the unique needs of family and provision of coordinated care in the home setting may become necessary as the patient approaches the terminal stage of decline.<xref ref-type="bibr" rid="article-25287.r108">[108]</xref>&#x000a0;Good end of life care may be provided by specialist palliative teams.<xref ref-type="bibr" rid="article-25287.r109">[109]</xref></p>
      </sec>
      <sec id="article-25287.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25287&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25287">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/motor-neuron-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25287">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25287/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25287">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25287.s15">
        <fig id="article-25287.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Clinical Examination of Ankle Clonus. Clinical examination of ankle clonus is typically demonstrated in upper motor neuron lesions or serotonin syndrome. Contributed by RS Menon, MD&#x000a0;</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Clinical__Examination__of__Ankle__Clonus.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25287.s16">
        <fig id="article-25287.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Simulation of Clasp Knife Reflex, Rigidity, Rapid decrease in resistance when attempting to flex a joint, Upper Motor Neuron Lesion Contributed by Dr. Raju S. Menon (https://www.youtube.com/watch?v=8xxe2WWWoYI)</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Simulation__of__Clasp__knife__Rigidity.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25287.s17">
        <fig id="article-25287.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Figure showing Labeled Motor Neuron. Contributed by Katherine Humphreys</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AxonMotorNeuron-01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25287.s18">
        <title>References</title>
        <ref id="article-25287.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al-Chalabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corr</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Robberecht</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Amyotrophic lateral sclerosis.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Oct</month>
            <day>05</day>
            <volume>3</volume>
            <fpage>17071</fpage>
            <pub-id pub-id-type="pmid">28980624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McVey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>735</fpage>
            <page-range>735-48</page-range>
            <pub-id pub-id-type="pmid">26515618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traynor</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Codd</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Corr</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Forde</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>OM</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study.</article-title>
            <source>Arch Neurol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>1171</fpage>
            <page-range>1171-6</page-range>
            <pub-id pub-id-type="pmid">10927797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ingre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roos</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Piehl</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for amyotrophic lateral sclerosis.</article-title>
            <source>Clin Epidemiol</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>181</fpage>
            <page-range>181-93</page-range>
            <pub-id pub-id-type="pmid">25709501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maessen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Veldink</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Onwuteaka-Philipsen</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Schelhaas</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Grupstra</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>van der Wal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Euthanasia and physician-assisted suicide in amyotrophic lateral sclerosis: a prospective study.</article-title>
            <source>J Neurol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>261</volume>
            <issue>10</issue>
            <fpage>1894</fpage>
            <page-range>1894-901</page-range>
            <pub-id pub-id-type="pmid">25022937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renton</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Chi&#x000f2;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Traynor</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>State of play in amyotrophic lateral sclerosis genetics.</article-title>
            <source>Nat Neurosci</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-23</page-range>
            <pub-id pub-id-type="pmid">24369373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Blitterswijk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeJesus-Hernandez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rademakers</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?</article-title>
            <source>Curr Opin Neurol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>689</fpage>
            <page-range>689-700</page-range>
            <pub-id pub-id-type="pmid">23160421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sayana</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Genetics of amyotrophic lateral sclerosis: an update.</article-title>
            <source>Mol Neurodegener</source>
            <year>2013</year>
            <month>Aug</month>
            <day>13</day>
            <volume>8</volume>
            <fpage>28</fpage>
            <pub-id pub-id-type="pmid">23941283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chi&#x000f2;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazzini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Alfonso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corrado</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Canosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moglia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manera</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bersano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brunetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barberis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Veldink</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sproviero</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vajda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rooney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Chalabi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The multistep hypothesis of ALS revisited: The role of genetic mutations.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Aug</month>
            <day>14</day>
            <volume>91</volume>
            <issue>7</issue>
            <fpage>e635</fpage>
            <page-range>e635-e642</page-range>
            <pub-id pub-id-type="pmid">30045958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LoRusso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hickman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Ion channel dysfunction and altered motoneuron excitability in ALS.</article-title>
            <source>Neurol Disord Epilepsy J</source>
            <year>2019</year>
            <volume>3</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32313901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volk</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Weishaupt</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kubisch</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis.</article-title>
            <source>Med Genet</source>
            <year>2018</year>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-258</page-range>
            <pub-id pub-id-type="pmid">30220791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozzoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pansarasa</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Diamanti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nosari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cereda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ceroni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Amyotrophic lateral sclerosis and environmental factors.</article-title>
            <source>Funct Neurol</source>
            <year>2016</year>
            <season>Jan-Mar</season>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-19</page-range>
            <pub-id pub-id-type="pmid">27027889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;n</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study.</article-title>
            <source>Eur J Neurol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>745</fpage>
            <page-range>745-51</page-range>
            <pub-id pub-id-type="pmid">19475756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gundogdu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Al-Lahham</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kadlubar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rudnicki</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Racial differences in motor neuron disease.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1-2</issue>
            <fpage>114</fpage>
            <page-range>114-8</page-range>
            <pub-id pub-id-type="pmid">24067242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boylan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Familial Amyotrophic Lateral Sclerosis.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>807</fpage>
            <page-range>807-30</page-range>
            <pub-id pub-id-type="pmid">26515623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijesekera</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Amyotrophic lateral sclerosis.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2009</year>
            <month>Feb</month>
            <day>03</day>
            <volume>4</volume>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">19192301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liewluck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saperstein</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Progressive Muscular Atrophy.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>761</fpage>
            <page-range>761-73</page-range>
            <pub-id pub-id-type="pmid">26515620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donnelly</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Grima</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sattler</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?</article-title>
            <source>Neurodegener Dis Manag</source>
            <year>2014</year>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>417</fpage>
            <page-range>417-37</page-range>
            <pub-id pub-id-type="pmid">25531686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Chern</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Energy Homeostasis and Abnormal RNA Metabolism in Amyotrophic Lateral Sclerosis.</article-title>
            <source>Front Cell Neurosci</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>126</fpage>
            <pub-id pub-id-type="pmid">28522961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van den Bos</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Geevasinga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Higashihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vucic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and Diagnosis of ALS: Insights from Advances in Neurophysiological Techniques.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jun</month>
            <day>10</day>
            <volume>20</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">31185581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukherjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Spasticity mechanisms - for the clinician.</article-title>
            <source>Front Neurol</source>
            <year>2010</year>
            <volume>1</volume>
            <fpage>149</fpage>
            <pub-id pub-id-type="pmid">21206767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bharathi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sivalingam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Girdhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis.</article-title>
            <source>Front Mol Neurosci</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">30837838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blokhuis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Groen</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Koppers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Pasterkamp</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Protein aggregation in amyotrophic lateral sclerosis.</article-title>
            <source>Acta Neuropathol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>125</volume>
            <issue>6</issue>
            <fpage>777</fpage>
            <page-range>777-94</page-range>
            <pub-id pub-id-type="pmid">23673820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McAlary</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plotkin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yerbury</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cashman</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis.</article-title>
            <source>Front Mol Neurosci</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>262</fpage>
            <pub-id pub-id-type="pmid">31736708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saberi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stauffer</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ravits</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>855</fpage>
            <page-range>855-76</page-range>
            <pub-id pub-id-type="pmid">26515626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Bech</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Frandsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schr&#x000f8;der</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Skeletal Muscle Remodelling as a Function of Disease Progression in Amyotrophic Lateral Sclerosis.</article-title>
            <source>Biomed Res Int</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>5930621</fpage>
            <pub-id pub-id-type="pmid">27195289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nijssen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Comley</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Hedlund</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis.</article-title>
            <source>Acta Neuropathol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>133</volume>
            <issue>6</issue>
            <fpage>863</fpage>
            <page-range>863-885</page-range>
            <pub-id pub-id-type="pmid">28409282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDermott</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of motor neurone disease.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Mar</month>
            <day>22</day>
            <volume>336</volume>
            <issue>7645</issue>
            <fpage>658</fpage>
            <page-range>658-62</page-range>
            <pub-id pub-id-type="pmid">18356234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mimics and chameleons in motor neurone disease.</article-title>
            <source>Pract Neurol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>153</fpage>
            <page-range>153-64</page-range>
            <pub-id pub-id-type="pmid">23616620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>A pattern recognition approach to patients with a suspected myopathy.</article-title>
            <source>Neurol Clin</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>569</fpage>
            <page-range>569-93, vii</page-range>
            <pub-id pub-id-type="pmid">25037080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ngo</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>McCombe</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Steyn</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions.</article-title>
            <source>Degener Neurol Neuromuscul Dis</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>95</fpage>
            <page-range>95-108</page-range>
            <pub-id pub-id-type="pmid">30050381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coccurello</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>What is "Hyper" in the ALS Hypermetabolism?</article-title>
            <source>Mediators Inflamm</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>7821672</fpage>
            <pub-id pub-id-type="pmid">29081604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guiloff</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Dysarthria in amyotrophic lateral sclerosis: A review.</article-title>
            <source>Amyotroph Lateral Scler</source>
            <year>2010</year>
            <volume>11</volume>
            <issue>1-2</issue>
            <fpage>4</fpage>
            <page-range>4-15</page-range>
            <pub-id pub-id-type="pmid">20184513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niedermeyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Respiratory Failure in Amyotrophic Lateral&#x000a0;Sclerosis.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>155</volume>
            <issue>2</issue>
            <fpage>401</fpage>
            <page-range>401-408</page-range>
            <pub-id pub-id-type="pmid">29990478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Willingham</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Roach</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kasarskis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Segerstrom</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Self-Regulation and Executive Functioning as Related to Survival in Motor Neuron Disease: Preliminary Findings.</article-title>
            <source>Psychosom Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>7</issue>
            <fpage>665</fpage>
            <page-range>665-672</page-range>
            <pub-id pub-id-type="pmid">29771729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kapogiannis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huey</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Momeni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>FTD and ALS: a tale of two diseases.</article-title>
            <source>Curr Alzheimer Res</source>
            <year>2011</year>
            <month>May</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-94</page-range>
            <pub-id pub-id-type="pmid">21222600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mioshi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Impact of Cognitive and Behavioral Symptoms on ALS Patients and Their Caregivers.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>192</fpage>
            <pub-id pub-id-type="pmid">30915018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pinto-Grau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lonergan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bede</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heverin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vajda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pender</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival.</article-title>
            <source>Ann Clin Transl Neurol</source>
            <year>2017</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>305</fpage>
            <page-range>305-317</page-range>
            <pub-id pub-id-type="pmid">28491898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piccione</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sletten</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Staff</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Autonomic system and amyotrophic lateral sclerosis.</article-title>
            <source>Muscle Nerve</source>
            <year>2015</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>676</fpage>
            <page-range>676-9</page-range>
            <pub-id pub-id-type="pmid">25211238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Vucic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yiannikas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Howells</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Matamala</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cornblath</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Differentiating lower motor neuron syndromes.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>88</volume>
            <issue>6</issue>
            <fpage>474</fpage>
            <page-range>474-483</page-range>
            <pub-id pub-id-type="pmid">28003344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sandner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasmantier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rowland</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Study of 962 patients indicates progressive muscular atrophy is a form of ALS.</article-title>
            <source>Neurology</source>
            <year>2009</year>
            <month>Nov</month>
            <day>17</day>
            <volume>73</volume>
            <issue>20</issue>
            <fpage>1686</fpage>
            <page-range>1686-92</page-range>
            <pub-id pub-id-type="pmid">19917992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Vries</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Rustemeijer</surname>
                <given-names>LMM</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Veldink</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Nijboer</surname>
                <given-names>TCW</given-names>
              </name>
              <name>
                <surname>van Es</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-147</page-range>
            <pub-id pub-id-type="pmid">30076267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Umbach</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Head injury and amyotrophic lateral sclerosis.</article-title>
            <source>Am J Epidemiol</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>166</volume>
            <issue>7</issue>
            <fpage>810</fpage>
            <page-range>810-6</page-range>
            <pub-id pub-id-type="pmid">17641152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowen</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alfahad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Oct</month>
            <day>25</day>
            <volume>87</volume>
            <issue>17</issue>
            <fpage>1756</fpage>
            <page-range>1756-1762</page-range>
            <pub-id pub-id-type="pmid">27664983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZY</given-names>
              </name>
            </person-group>
            <article-title>Amyotrophic Lateral Sclerosis: Precise Diagnosis and Individualized Treatment.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2017</year>
            <month>Oct</month>
            <day>05</day>
            <volume>130</volume>
            <issue>19</issue>
            <fpage>2269</fpage>
            <page-range>2269-2272</page-range>
            <pub-id pub-id-type="pmid">28937029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benbrika</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desgranges</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eustache</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Viader</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Cognitive, Emotional and Psychological Manifestations in Amyotrophic Lateral Sclerosis at Baseline and Overtime: A Review.</article-title>
            <source>Front Neurosci</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>951</fpage>
            <pub-id pub-id-type="pmid">31551700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bali</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Management of amyotrophic lateral sclerosis.</article-title>
            <source>Mo Med</source>
            <year>2013</year>
            <season>Sep-Oct</season>
            <volume>110</volume>
            <issue>5</issue>
            <fpage>417</fpage>
            <page-range>417-21</page-range>
            <pub-id pub-id-type="pmid">24279194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benny</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The split hand sign.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-6</page-range>
            <pub-id pub-id-type="pmid">22919187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical Mimickers of Amyotrophic Lateral Sclerosis-Conditions We Cannot Afford to Miss.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-178</page-range>
            <pub-id pub-id-type="pmid">30258257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finegan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chipika</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Li Hi Shing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bede</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>260</fpage>
            <pub-id pub-id-type="pmid">30949121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Motor neurone disease: diagnostic pitfalls.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-100</page-range>
            <pub-id pub-id-type="pmid">23472505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders.</article-title>
            <source>Curr Pharm Des</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>43</issue>
            <fpage>4560</fpage>
            <page-range>4560-4569</page-range>
            <pub-id pub-id-type="pmid">31820696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verber</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Shepheard</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sassani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonough</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alix</surname>
                <given-names>JJP</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers in Motor Neuron Disease: A State of the Art Review.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>291</fpage>
            <pub-id pub-id-type="pmid">31001186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rammes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zieglg&#x000e4;nsberger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>115</volume>
            <issue>8</issue>
            <fpage>1119</fpage>
            <page-range>1119-26</page-range>
            <pub-id pub-id-type="pmid">18493706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinchcliffe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis.</article-title>
            <source>Degener Neurol Neuromuscul Dis</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>61</fpage>
            <page-range>61-70</page-range>
            <pub-id pub-id-type="pmid">30050378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dharmadasa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Riluzole, disease stage and survival in ALS.</article-title>
            <source>Lancet Neurol</source>
            <year>2018</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>385</fpage>
            <page-range>385-386</page-range>
            <pub-id pub-id-type="pmid">29525493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2002</year>
            <issue>2</issue>
            <fpage>CD001447</fpage>
            <pub-id pub-id-type="pmid">12076411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Mar</month>
            <day>14</day>
            <volume>2012</volume>
            <issue>3</issue>
            <fpage>CD001447</fpage>
            <pub-id pub-id-type="pmid">22419278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falc&#x000e3;o de Campos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Carvalho</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Riluzole-induced recurrent pancreatitis.</article-title>
            <source>J Clin Neurosci</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>45</volume>
            <fpage>153</fpage>
            <page-range>153-154</page-range>
            <pub-id pub-id-type="pmid">28867362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siniscalchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Tolerability of riluzole: a review of the literature].</article-title>
            <source>Clin Ter</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>155</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-8</page-range>
            <pub-id pub-id-type="pmid">15147078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bensimon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Doble</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>525</fpage>
            <page-range>525-34</page-range>
            <pub-id pub-id-type="pmid">15500412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Edaravone and its clinical development for amyotrophic lateral sclerosis.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>sup1</issue>
            <fpage>5</fpage>
            <page-range>5-10</page-range>
            <pub-id pub-id-type="pmid">28872907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turnbull</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Is edaravone harmful? (A placebo is not a control).</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>7-8</issue>
            <fpage>477</fpage>
            <page-range>477-482</page-range>
            <pub-id pub-id-type="pmid">30373406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawada</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2017</year>
            <month>May</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>735</fpage>
            <page-range>735-738</page-range>
            <pub-id pub-id-type="pmid">28406335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Primary Lateral Sclerosis.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>749</fpage>
            <page-range>749-60</page-range>
            <pub-id pub-id-type="pmid">26515619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balci</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Spasticity Measurement.</article-title>
            <source>Noro Psikiyatr Ars</source>
            <year>2018</year>
            <volume>55</volume>
            <issue>Suppl 1</issue>
            <fpage>S49</fpage>
            <page-range>S49-S53</page-range>
            <pub-id pub-id-type="pmid">30692856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Clinical diagnosis and management of amyotrophic lateral sclerosis.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2011</year>
            <month>Oct</month>
            <day>11</day>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>639</fpage>
            <page-range>639-49</page-range>
            <pub-id pub-id-type="pmid">21989247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barzegar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Baclofen Induced Encephalopathy in a 6-Year-Old Boy with Advanced Renal Failure.</article-title>
            <source>Iran J Child Neurol</source>
            <year>2015</year>
            <season>Spring</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-3</page-range>
            <pub-id pub-id-type="pmid">26221166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <collab>Medical Advisory Secretariat</collab>
            <article-title>Intrathecal baclofen pump for spasticity: an evidence-based analysis.</article-title>
            <source>Ont Health Technol Assess Ser</source>
            <year>2005</year>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>1</fpage>
            <page-range>1-93</page-range>
            <pub-id pub-id-type="pmid">23074476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sathasivam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pih</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>May</month>
            <day>11</day>
            <issue>5</issue>
            <fpage>CD006981</fpage>
            <pub-id pub-id-type="pmid">21563158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Huebers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1756285617734734</fpage>
            <pub-id pub-id-type="pmid">29399045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brettschneider</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kurent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <day>05</day>
            <volume>2013</volume>
            <issue>6</issue>
            <fpage>CD005226</fpage>
            <pub-id pub-id-type="pmid">23740607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiousi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arnaoutoglou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Printza</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Speech and language intervention for language impairment in patients in the FTD-ALS spectrum.</article-title>
            <source>Hell J Nucl Med</source>
            <year>2019</year>
            <season>Jan-Apr</season>
            <volume>22 Suppl</volume>
            <fpage>133</fpage>
            <page-range>133-146</page-range>
            <pub-id pub-id-type="pmid">30877731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Luca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Virtuoso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maggio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Papa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases.</article-title>
            <source>Int J Mol Sci</source>
            <year>2017</year>
            <month>Oct</month>
            <day>12</day>
            <volume>18</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">29023416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mioshi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramsey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devenney</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hornberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Jan</month>
            <day>14</day>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-55</page-range>
            <pub-id pub-id-type="pmid">24336140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Katipally</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Schanz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Stephen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Danielian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huey</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Meoded</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Aug</month>
            <day>12</day>
            <volume>83</volume>
            <issue>7</issue>
            <fpage>620</fpage>
            <page-range>620-7</page-range>
            <pub-id pub-id-type="pmid">25008395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mariosa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ingre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lundholm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wirdefeldt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roos</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Depression in amyotrophic lateral sclerosis.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Jun</month>
            <day>14</day>
            <volume>86</volume>
            <issue>24</issue>
            <fpage>2271</fpage>
            <page-range>2271-7</page-range>
            <pub-id pub-id-type="pmid">27164661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Pseudobulbar affect: prevalence and management.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2013</year>
            <volume>9</volume>
            <fpage>483</fpage>
            <page-range>483-9</page-range>
            <pub-id pub-id-type="pmid">24348042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nichols</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Van Dyke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nashold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Satriotomo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Ventilatory control in ALS.</article-title>
            <source>Respir Physiol Neurobiol</source>
            <year>2013</year>
            <month>Nov</month>
            <day>01</day>
            <volume>189</volume>
            <issue>2</issue>
            <fpage>429</fpage>
            <page-range>429-37</page-range>
            <pub-id pub-id-type="pmid">23692930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Carvalho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swash</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diaphragmatic Neurophysiology and Respiratory Markers in ALS.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>143</fpage>
            <pub-id pub-id-type="pmid">30846968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lechtzin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wiener</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shade</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Clawson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Diette</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis.</article-title>
            <source>Chest</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>436</fpage>
            <page-range>436-42</page-range>
            <pub-id pub-id-type="pmid">11834654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacombe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Del Amo Castrillo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chapeau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horvat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vaugier</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lejaille</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orlikowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prigent</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lofaso</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Comparison of three cough-augmentation techniques in neuromuscular patients: mechanical insufflation combined with manually assisted cough, insufflation-exsufflation alone and insufflation-exsufflation combined with manually assisted cough.</article-title>
            <source>Respiration</source>
            <year>2014</year>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-22</page-range>
            <pub-id pub-id-type="pmid">25171575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>HWB</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>YKJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>OMI</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Supportive &#x00026; palliative interventions in motor neurone disease: what we know from current literature?</article-title>
            <source>Ann Palliat Med</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>320</fpage>
            <page-range>320-331</page-range>
            <pub-id pub-id-type="pmid">29156920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sancho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bures</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ponz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Servera</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Bulbar impairment score and survival of stable amyotrophic lateral sclerosis patients after noninvasive ventilation initiation.</article-title>
            <source>ERJ Open Res</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29670892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bach</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aufiero</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Oximetry and indications for tracheotomy for amyotrophic lateral sclerosis.</article-title>
            <source>Chest</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>126</volume>
            <issue>5</issue>
            <fpage>1502</fpage>
            <page-range>1502-7</page-range>
            <pub-id pub-id-type="pmid">15539719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Pimpec-Barthes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Legras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arame</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pricopi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boucherie</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Badia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panzini</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Diaphragm pacing: the state of the art.</article-title>
            <source>J Thorac Dis</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>Suppl 4</issue>
            <fpage>S376</fpage>
            <page-range>S376-86</page-range>
            <pub-id pub-id-type="pmid">27195135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibbons</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pagnini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Friede</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Jan</month>
            <day>02</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD011005</fpage>
            <pub-id pub-id-type="pmid">29293261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karam</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Paganoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Bedlack</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.</article-title>
            <source>Am J Hosp Palliat Care</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">25202033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zwicker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Talarico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bourque</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chin-Yee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tanuseputro</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Dying of amyotrophic lateral sclerosis: Health care use and cost in the last year of life.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Dec</month>
            <day>03</day>
            <volume>93</volume>
            <issue>23</issue>
            <fpage>e2083</fpage>
            <page-range>e2083-e2093</page-range>
            <pub-id pub-id-type="pmid">31672715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazutti</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Fumis</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Limitation to Advanced Life Support in patients admitted to intensive care unit with integrated palliative care.</article-title>
            <source>Rev Bras Ter Intensiva</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>294</fpage>
            <page-range>294-300</page-range>
            <pub-id pub-id-type="pmid">27626949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bello-Haas</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Physical therapy for individuals with amyotrophic lateral sclerosis: current insights.</article-title>
            <source>Degener Neurol Neuromuscul Dis</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">30890895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beukelman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fager</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nordness</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Communication Support for People with ALS.</article-title>
            <source>Neurol Res Int</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>714693</fpage>
            <pub-id pub-id-type="pmid">21603029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ciotti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cohen-Tannoudji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Biferi</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Gene Therapy for ALS-A Perspective.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Sep</month>
            <day>06</day>
            <volume>20</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">31500113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lunn</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sakowski</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.</article-title>
            <source>Stem Cells</source>
            <year>2014</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>1099</fpage>
            <page-range>1099-109</page-range>
            <pub-id pub-id-type="pmid">24448926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawson</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2014</year>
            <volume>10</volume>
            <fpage>567</fpage>
            <page-range>567-76</page-range>
            <pub-id pub-id-type="pmid">24741315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feinberg</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Radecki</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Parsonage-turner syndrome.</article-title>
            <source>HSS J</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-205</page-range>
            <pub-id pub-id-type="pmid">21886536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aundhakar</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Chhapra</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Hirayama's Disease: A Rare Clinical Variant of Amyotrophic Lateral Sclerosis.</article-title>
            <source>Adv Biomed Res</source>
            <year>2017</year>
            <volume>6</volume>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">28828346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koutsis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.</article-title>
            <source>J Neurol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>266</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-573</page-range>
            <pub-id pub-id-type="pmid">30006721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Inclusion body myositis.</article-title>
            <source>Neurol Clin</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-46, vii</page-range>
            <pub-id pub-id-type="pmid">25037082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chi&#x000f2;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Swingler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beghi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Traynor</surname>
                <given-names>BG</given-names>
              </name>
              <collab>Eurals Consortium</collab>
            </person-group>
            <article-title>Prognostic factors in ALS: A critical review.</article-title>
            <source>Amyotroph Lateral Scler</source>
            <year>2009</year>
            <season>Oct-Dec</season>
            <volume>10</volume>
            <issue>5-6</issue>
            <fpage>310</fpage>
            <page-range>310-23</page-range>
            <pub-id pub-id-type="pmid">19922118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chi&#x000f2;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonito</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">24336810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crockford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lonergan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chiwera</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colville</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heverin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mays</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pender</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pinto-Grau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radakovic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swingler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vajda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Chalabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Abrahams</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Oct</month>
            <day>09</day>
            <volume>91</volume>
            <issue>15</issue>
            <fpage>e1370</fpage>
            <page-range>e1370-e1380</page-range>
            <pub-id pub-id-type="pmid">30209236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>McVey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rudnicki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>889</fpage>
            <page-range>889-908</page-range>
            <pub-id pub-id-type="pmid">26515628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cichero</surname>
                <given-names>JAY</given-names>
              </name>
            </person-group>
            <article-title>Age-Related Changes to Eating and Swallowing Impact Frailty: Aspiration, Choking Risk, Modified Food Texture and Autonomy of Choice.</article-title>
            <source>Geriatrics (Basel)</source>
            <year>2018</year>
            <month>Oct</month>
            <day>12</day>
            <volume>3</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31011104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Risk of developing pressure sore in amyotrophic lateral sclerosis patients - a nationwide cohort study.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>1589</fpage>
            <page-range>1589-1596</page-range>
            <pub-id pub-id-type="pmid">29512203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gladman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dehaan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Geerts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>May</month>
            <day>13</day>
            <volume>82</volume>
            <issue>19</issue>
            <fpage>1674</fpage>
            <page-range>1674-7</page-range>
            <pub-id pub-id-type="pmid">24727309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smithson</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Integrating the algorithm into community practice.</article-title>
            <source>Neurology</source>
            <year>1999</year>
            <volume>53</volume>
            <issue>8 Suppl 5</issue>
            <fpage>S63</fpage>
            <page-range>S63-6; discussion S67-71</page-range>
            <pub-id pub-id-type="pmid">10560642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aoun</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>205</fpage>
            <page-range>205-215</page-range>
            <pub-id pub-id-type="pmid">28579792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25287.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliver</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Palliative care in motor neurone disease: where are we now?</article-title>
            <source>Palliat Care</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1178224218813914</fpage>
            <pub-id pub-id-type="pmid">30718958</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
